# Karthik Ramasamy

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 145 papers | 2,092 citations | 257450 24 h-index | 276875 41 g-index |
| 148 all docs | 148 docs citations | 148 times ranked | 2494 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794. | 10.7 | 254 |
| 2 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264. | 13.7 | 187 |
| 3 | Dhalion. Proceedings of the VLDB Endowment, 2017, 10, 1825-1836. | 3.8 | 106 |
| 4 | Realâ€world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVIDâ€19 disease) in patients with multiple myeloma receiving systemic antiâ€cancer therapy. British Journal of Haematology, 2020, 190, e83-e86. | 2.5 | 92 |
| 5 | Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood, 2021, 137, 232-237. | 1.4 | 90 |
| 6 | Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17. | 6.2 | 75 |
| 7 | Serum-free light-chain assay: clinical utility and limitations. Annals of Clinical Biochemistry, 2014, 51, 528-542. | 1.6 | 59 |
| 8 | The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology, 2010, 150, 326-333. | 2.5 | 57 |
| 9 | Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Journal of Clinical Oncology, 2018, 36, 2035-2043. | 1.6 | 55 |
| 10 | Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Advances, 2019, 3, 2409-2423. | 5.2 | 48 |
| 11 | Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease. Nature Communications, 2019, 10, 4533. | 12.8 | 46 |
| 12 | Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40. | 6.2 | 46 |
| 13 | First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8500-8500. | 1.6 | 40 |
| 14 | Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. British Journal of Haematology, 2011, 155, 632-634. | 2.5 | 39 |
| 15 | Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. British Journal of Haematology, 2007, 137, 374-375. | 2.5 | 38 |
| 16 | Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology, 2020, 99, 1049-1061. | 1.8 | 31 |
| 17 | Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leukemia Research, 2017, 59, 75-84. | 0.8 | 30 |
| 18 | Pomalidomide therapy for myeloma. Expert Opinion on Investigational Drugs, 2011, 20, 691-700. | 4.1 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Multiple myeloma in the very elderly patient: challenges and solutions. Clinical Interventions in Aging, 2016, 11, 423. | 2.9 | 28 |
| 20 | Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Reviews, 2021, 49, 100808. | 5.7 | 27 |
| 21 | Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplantation, 2006, 38, 823-824. | 2.4 | 26 |
| 22 | Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis. BMJ Open, 2018, 8, e019758. | 1.9 | 26 |
| 23 | Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212. | 7.0 | 26 |
| 24 | Rituximab and thalidomide combination therapy for Castleman disease. British Journal of Haematology, 2012, 158, 421-423. | 2.5 | 25 |
| 25 | Optimizing the management of patients with spinal myeloma disease. British Journal of Haematology, 2015, 171, 332-343. | 2.5 | 25 |
| 26 | Realâ€world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multiâ€centre <scp>UK</scp> experience. British Journal of Haematology, 2017, 176, 908-917. | 2.5 | 25 |
| 27 | Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Journal of Clinical Oncology, 2021, 39, 227-237. | 1.6 | 22 |
| 28 | Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: Report of three cases and review of literature. Leukemia and Lymphoma, 2007, 48, 290-294. | 1.3 | 19 |
| 29 | Circulating DNA: a potential marker of sickle cell crisis. British Journal of Haematology, 2007, 139, 331-336. | 2.5 | 19 |
| 30 | Time to redefine Myeloma. British Journal of Haematology, 2015, 171, 1-10. | 2.5 | 18 |
| 31 | Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome. Annals of Hematology, 2006, 85, 629-630. | 1.8 | 17 |
| 32 | Fluorescenceâ€based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. British Journal of Haematology, 2012, 157, 564-579. | 2.5 | 17 |
| 33 | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia, 2020, 34, 3019-3027. | 7.2 | 17 |
| 34 | Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 1926-1937. | 2.0 | 16 |
| 35 | Immune response to <scp>COVID</scp>â€19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent Tâ€cell response. British Journal of Haematology, 2022, 197, 293-301. | 2.5 | 16 |
| 36 | Treat or palliate: outcomes of very elderly myeloma patients. Haematologica, 2018, 103, e32-e34. | 3.5 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of Bone Oncology, 2019, 17, 100243. | 2.4 | 15 |
| 38 | Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 572-587. | 0.4 | 15 |
| 39 | Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Scientific Reports, 2019, 9, 14189. | 3.3 | 14 |
| 40 | Long term outcomes in monoclonal gammopathy of renal significance. British Journal of Haematology, 2019, 186, 706-716. | 2.5 | 14 |
| 41 | Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phaseï»¿ 2 trial. Blood Cancer Journal, 2022, 12, 9. | 6.2 | 14 |
| 42 | Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica, 2006, 91, ECR44. | 3.5 | 14 |
| 43 | Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Annals of Hematology, 2015, 94, 643-649. | 1.8 | 13 |
| 44 | Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. PLoS ONE, 2019, 14, e0219857. | 2.5 | 13 |
| 45 | COVID symptoms, testing, shielding impact on patientâ€reported outcomes and early vaccine responses in individuals with multiple myeloma. British Journal of Haematology, 2022, 196, 95-98. | 2.5 | 13 |
| 46 | Realâ€world treatment patterns and outcomes in nonâ€transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. European Journal of Haematology, 2020, 105, 308-325. | 2.2 | 11 |
| 47 | Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 47-48. | 1.4 | 11 |
| 48 | Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care. Haematologica, 2020, 105, e474-479. | 3.5 | 10 |
| 49 | Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLoS ONE, 2015, 10, e0136207. | 2.5 | 10 |
| 50 | Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open, 2021, 11, e052759. | 1.9 | 9 |
| 51 | Potential â€˜significanceâ€™ of monoclonal gammopathy of â€˜undetermined significanceâ€™ during COVID-19 pandemic. Blood Cells, Molecules, and Diseases, 2020, 85, 102481. | 1.4 | 8 |
| 52 | Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology, 2021, 193, 750-760. | 2.5 | 8 |
| 53 | The management of Castleman disease. British Journal of Haematology, 2021, 195, 328-337. | 2.5 | 8 |
| 54 | Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures. Rheumatology, 2019, 58, 1142-1153. | 1.9 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. PLoS ONE, 2020, 15, e0229469. | 2.5 | 7 |
| 56 | COVIDâ€19 and myeloma clinical research â€“ experience from the CARDAMON clinical trial. British Journal of Haematology, 2021, 192, e14-e16. | 2.5 | 7 |
| 57 | Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study. Blood, 2019, 134, 861-861. | 1.4 | 7 |
| 58 | Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.. Journal of Clinical Oncology, 2019, 37, 8016-8016. | 1.6 | 7 |
| 59 | Managing multiple myeloma in the over 70s: A review. Maturitas, 2015, 80, 148-154. | 2.4 | 6 |
| 60 | Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica, 2021, 106, 2694-2706. | 3.5 | 6 |
| 61 | Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. Blood, 2018, 132, 802-802. | 1.4 | 6 |
| 62 | Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis. Blood, 2015, 126, 374-374. | 1.4 | 6 |
| 63 | Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. Blood, 2017, 130, 835-835. | 1.4 | 6 |
| 64 | Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS ONE, 2022, 17, e0270854. | 2.5 | 6 |
| 65 | Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leukemia and Lymphoma, 2020, 61, 668-679. | 1.3 | 5 |
| 66 | Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins. Clinical Biochemistry, 2021, 95, 81-83. | 1.9 | 5 |
| 67 | A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 2021, 11, 149. | 6.2 | 5 |
| 68 | Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (â‰¥2nd) Tj ETQq0 0 0 rgBT /Overlock 1 1396-1404. | 1.3 | 5 |
| 69 | Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia â€“ A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 242-245. | 0.4 | 4 |
| 70 | Clinical outcomes of bortezomib-based therapy in myeloma. PLoS ONE, 2018, 13, e0208920. | 2.5 | 4 |
| 71 | Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma. Blood, 2020, 136, 12-14. | 1.4 | 4 |
| 72 | Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. Blood, 2020, 136, 42-44. | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology, 2022, 27, 691-699. | 1.5 | 4 |
| 74 | Reducing infection-related morbidity and mortality in patients with myeloma. Lancet Oncology, The, 2019, 20, 1633-1635. | 10.7 | 3 |
| 75 | In-house age-specific reference ranges for free light chains measured on the SPAPlusÂ® analyser. Annals of Clinical Biochemistry, 2020, 57, 138-143. | 1.6 | 3 |
| 76 | Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma. Leukemia and Lymphoma, 2020, 61, 732-736. | 1.3 | 3 |
| 77 | Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report. BMJ Open Quality, 2021, 10, e001085. | 1.1 | 3 |
| 78 | Validation of clinicalâ€grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newlyâ€diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. EJHaem, 2021, 2, 809. | 1.0 | 3 |
| 79 | Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study. Blood, 2018, 132, 306-306. | 1.4 | 3 |
| 80 | Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8531-8531. | 1.6 | 3 |
| 81 | Multiple myeloma screening within a fracture liaison service (FLS). Osteoporosis International, 2022, 33, 937-941. | 3.1 | 3 |
| 82 | Ambulatory therapy of patients with free-floating proximal deep vein thrombosis is safe. Thrombosis and Haemostasis, 2005, 94, 1343-1344. | 3.4 | 2 |
| 83 | Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma. British Journal of Haematology, 2019, 185, 775-778. | 2.5 | 2 |
| 84 | Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience. British Journal of Haematology, 2020, 188, e57-e60. | 2.5 | 2 |
| 85 | Myeloma care adaptations in the UK during SARSâ€CoVâ€2 pandemic: Challenges and measurable outcomes. European Journal of Haematology, 2020, 105, 662-666. | 2.2 | 2 |
| 86 | Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e769-e776. | 0.4 | 2 |
| 87 | DPACEâ€based chemotherapy in the era of myeloma novel agents: A UK multicentre study. European Journal of Haematology, 2020, 105, 231-233. | 2.2 | 2 |
| 88 | Myeloma clinical outcomes following the first wave of COVIDâ€19: results from the Thames Valley Cancer Alliance (UK). British Journal of Haematology, 2021, 192, e136-e139. | 2.5 | 2 |
| 89 | Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.. Journal of Clinical Oncology, 2021, 39, 8020-8020. | 1.6 | 2 |
| 90 | Hevylite and Freelite Normalisation Is a Surrogate Marker for MRD Negativity Post-ASCT. Blood, 2016, 128, 4633-4633. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, TPS8054-TPS8054. | 1.6 | 2 |
| 92 | Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity. Blood, 2018, 132, 3300-3300. | 1.4 | 2 |
| 93 | Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min. Blood, 2019, 134, 3135-3135. | 1.4 | 2 |
| 94 | Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect Â® Multiple Myeloma (MM) Disease Registry. Blood, 2021, 138, 117-117. | 1.4 | 2 |
| 95 | The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice. Blood, 2021, 138, 2701-2701. | 1.4 | 2 |
| 96 | Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort. Journal of Oncology Pharmacy Practice, 2023, 29, 299-304. | 0.9 | 2 |
| 97 | PF599 EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL. HemaSphere, 2019, 3, 252-253. | 2.7 | 1 |
| 98 | Efficacy and tolerability of VCD chemotherapy in a UK realâ€world dataset of elderly transplantâ€ineligible newly diagnosed myeloma patients. European Journal of Haematology, 2021, 106, 563-573. | 2.2 | 1 |
| 99 | Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105. | 2.4 | 1 |
| 100 | Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity. Blood, 2018, 132, 2648-2648. | 1.4 | 1 |
| 101 | Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis. Blood, 2018, 132, 4744-4744. | 1.4 | 1 |
| 102 | Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018. Blood, 2018, 132, 4743-4743. | 1.4 | 1 |
| 103 | Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib. Blood, 2010, 116, 1931-1931. | 1.4 | 1 |
| 104 | Podia in Multiple Myeloma (MM) Cells Promote Adhesion with Bone Marrow (BM) Fibroblastic Stromal Cells. Blood, 2011, 118, 626-626. | 1.4 | 1 |
| 105 | PS1388 RELATIVE EFFICACY OF APPROVED AND RECENTLY INTRODUCED TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A NETWORK META-ANALYSIS. HemaSphere, 2019, 3, 636. | 2.7 | 1 |
| 106 | Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project. Blood, 2019, 134, 3062-3062. | 1.4 | 1 |
| 107 | OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S2-S3. | 0.4 | 1 |
| 108 | Efficacy Outcomes of Isatuximab with Pomalidomide and Dexamethasone Are Comparable to (ICARIA-MM) Trial Data: Initial Results of a UK-Wide Real-World Study of Relapsed Myeloma Patients. Blood, 2021, 138, 1963-1963. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma. Blood, 2021, 138, 2676-2676. | 1.4 | 1 |
| 110 | BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. Expert Review of Hematology, 2022, 15, 503-517. | 2.2 | 1 |
| 111 | Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset. HemaSphere, 2022, 6, e738. | 2.7 | 1 |
| 112 | Mott cells in CD20-positive myeloma. British Journal of Haematology, 2011, 152, 366-366. | 2.5 | 0 |
| 113 | Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma - response to Grey-Davies etÂal. British Journal of Haematology, 2012, 156, 555-555. | 2.5 | 0 |
| 114 | Castlemanâ€™s disease. , 0, , 216-224. | | 0 |
| 115 | Resource implications of bortezomib therapy in a large UK cohort: An evaluation study. Journal of Oncology Pharmacy Practice, 2019, 25, 1995-1998. | 0.9 | 0 |
| 116 | PS1411 CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NONâ€STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE. HemaSphere, 2019, 3, 648-649. | 2.7 | 0 |
| 117 | Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e225-e226. | 0.4 | 0 |
| 118 | Consolidation following DPACE therapy improves outcomes in relapsed/refractory myeloma patients in the era of novel agents. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e254-e255. | 0.4 | 0 |
| 119 | PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTHâ€RELATED QUALITY OF LIFE IN TRANSPLANTâ€INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (Dâ€RD) VS RD: MAIA. HemaSphere, 2019, 3, 255. | 2.7 | 0 |
| 120 | PB2117ÂPOMALIDOMIDE PLUS LOWâ€DEXAMETHASONE TREATMENT FOR â‰¥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MMâ€013ÂPHASE 2 STUDY. HemaSphere, 2019, 3, 953. | 2.7 | 0 |
| 121 | Pomalidomide and Dexamethasone Treatment for â‰¥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e284-e285. | 0.4 | 0 |
| 122 | Haemophagocytic Lymphohistiocytosis Post Liver Transplantation.. Blood, 2004, 104, 3822-3822. | 1.4 | 0 |
| 123 | Bevacizumab Therapy for POEMS Syndrome.. Blood, 2006, 108, 5108-5108. | 1.4 | 0 |
| 124 | Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).. Blood, 2007, 110, 3034-3034. | 1.4 | 0 |
| 125 | Novel In Vitro Experimental Platform for High Throughput Analysis of the Effect of Drugs on Multiple Myeloma Cells and the Tumour Microenvironment In a Co-Culture Setting. Blood, 2010, 116, 982-982. | 1.4 | 0 |
| 126 | Beta7 Integrins Regulate Podia Formation in Multiple Myeloma (MM) Cells for the Interaction with the Cellular and Non-Cellular Bone Marrow (BM) Stroma. Blood, 2012, 120, 3979-3979. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Transcriptome Profiling of the Myeloma-Bone Niche Identifies BMP Signaling Role in Bone Destruction and Niche Maintenance, and Potential As a Therapeutic Target. Blood, 2016, 128, 483-483. | 1.4 | 0 |
| 128 | Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS). Blood, 2016, 128, 5948-5948. | 1.4 | 0 |
| 129 | Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Blood, 2016, 128, 3311-3311. | 1.4 | 0 |
| 130 | Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 2013-2013. | 1.4 | 0 |
| 131 | PF629 CONSOLIDATION FOLLOWING INFUSIONAL DPACE IMPROVES OUTCOMES IN NOVEL AGENT RELAPSED/REFRACTORY MYELOMA PATIENTS. HemaSphere, 2019, 3, 267-268. | 2.7 | 0 |
| 132 | PS1416 EVOLVING TREATMENT PATTERNS IN NON-STEM CELL TRANSPLANT (NSCT) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS FROM A REAL-WORLD CHART REVIEW IN FRANCE, GERMANY, AND THE UK. HemaSphere, 2019, 3, 651. | 2.7 | 0 |
| 133 | PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POSTâ€AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSIONâ€FREE SURVIVAL â€“ ANALYSIS FROM THE TOURMALINEâ€MM3 STUDY. HemaSphere, 2019, 3, 632-633. | 2.7 | 0 |
| 134 | Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care. Blood, 2019, 134, 4768-4768. | 1.4 | 0 |
| 135 | Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open, 2021, 11, e052759. | 1.9 | 0 |
| 136 | Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma. Blood, 2021, 138, 890-890. | 1.4 | 0 |
| 137 | Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. Blood, 2021, 138, 2911-2911. | 1.4 | 0 |
| 138 | PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study. Blood, 2021, 138, 2750-2750. | 1.4 | 0 |
| 139 | REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study. Blood, 2021, 138, 1967-1967. | 1.4 | 0 |
| 140 | Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. Blood, 2021, 138, 1631-1631. | 1.4 | 0 |
| 141 | Bone Pain As a Presenting Symptom in Patients with Newly Diagnosed Multiple Myeloma in the Primary Care Setting: A Population-Based Cohort Study. Blood, 2020, 136, 18-18. | 1.4 | 0 |
| 142 | Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial. Blood, 2020, 136, 5-6. | 1.4 | 0 |
| 143 | Prospective Study Reveals Increased Platelet Function Associated with Multiple Myeloma and Its Treatment. Blood, 2020, 136, 21-21. | 1.4 | 0 |
| 144 | Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Generic Lenalidomide: An opportunity to address the balance of administrative burden and drug safety. European Journal of Haematology, 2022, 109, 305-306. | 2.2 | 0 |